Updated results from TIGER-X, a phase open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). Goldman, J., Soria, J., Wakelee, H. A., Camidge, D., Gadgeel, S. M., Yu, H., Reckamp, K. L., Papadimitrakopoulou, V., Perol, M., Ou, S., Matheny, S. L., Despain, D., Isaacson, J. D., Yurasov, S., Rolfe, L., Sequis, L. V. AMER SOC CLINICAL ONCOLOGY. 2016

View details for DOI 10.1200/JCO.2016.34.15_suppl.9045

View details for Web of Science ID 000404711506193